Have any questions? 706-721-6582 or cts@augusta.edu
- Georgetown STUDY00003849: A phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer
Clinical Trial
Georgetown STUDY00003849: A phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer
This is a phase II, open-label treatment study for women with locally advanced or metastatic cervical cancer, who will receive treatment with a combination of Pembrolizumab and Lenvatinib to determine the response rate (how well the cancer responds to this therapy regimen). Subjects will participate in this study for 24 months.
- Female Reproductive System
- Gyn-oncology- Advanced Cervical Cancer
- Gynecologic Oncology
- Gynecologic- Cervical Cancer
Eligibility Criteria
- Brief inclusion criteria: Adults 18 years and older Non-pregnant or breastfeeding female Confirmed diagnosis of cervical cancer Brief exclusion criteria: Pregnant and/or breastfeeding female Uncontrolled high blood pressure Bleeding or blood clot disorder which would put the patient at risk of hemorrhage Abnormal lab results (that do not meet the screening criteria).
RESEARCH. INNOVATION. DISCOVERY.